Scientists at BCI have uncovered an important way that cells keep their genes under control. The discovery could help explain one of the earliest molecular changes that occurs during the development of lung cancer. 🧪 #MedSky #OncoSky @qmul.bsky.social

Protein lost in lung cancer reveals hidden layer of gene control - Barts Cancer Institute

Scientists at Barts Cancer Institute, Queen Mary University of London, have uncovered an important way that cells keep their genes under control. The discovery could help explain one of the earliest m...

bci.qmul.ac.uk

How can artificial intelligence help us spot the faint signs of cancer in a blood sample? Prof Nitzan Rosenfeld and team at BCI @qmul.bsky.social have developed a new AI tool that combines multiple clues carried by DNA fragments in the blood. 🧪 #medsky #oncosky @cancerresearchuk.org

AI combines multiple DNA clues to improve cancer detection from blood - Barts Cancer Institute

Researchers have developed an artificial intelligence method that can detect signs of cancer by combining several different clues found in DNA fragments circulating in the blood. The method, developed...

bci.qmul.ac.uk

The major drivers of liver cancer are largely preventable – yet public awareness of the disease remains low.

Liver cancer deaths are rapidly increasing – tackling preventable causes would save lives

The major drivers of liver cancer are largely preventable – yet public awareness of the disease remains low.

tcnv.link

Paulo Ribeiro, @aashikasekar.bsky.social et al @qmbci.bsky.social find that protein phosphatase PP2A activates the Hippo pathway in Drosophila, in addition to its role as a Hippo negative regulator as part of the STRIPAK complex link.springer.com/article/10.1...

PP2A phosphatase regulates Hippo signalling in dual manner - The EMBO Journal

Hippo signalling is an evolutionarily conserved pathway that regulates tissue growth. The FERM domain protein Expanded (Ex) integrates polarity cues to activate the Hippo pathway. Previous work has sh...

link.springer.com

Congratulations to Dr Gabriella Ficz and team (@ficzlab.bsky.social), who have been awarded £880,000 as part of a £5.7m collaboration 'epiPRIME' exploring a new approach to antiviral protection, funded by ‪@aria-research.bsky.social today. @qmul.bsky.social @qmulfmd.bsky.social 🧪

Scientists awarded £5.7m to harness epigenetics in next-generation anti-viral therapies

Researchers at Barts Cancer Institute, Queen Mary University of London, have been awarded funding as part of a £5.7m national collaborative initiative exploring how epigenetics – the processes that co...

bci.qmul.ac.uk

Triple-negative breast cancer can be difficult to treat, partly because immune cells may struggle to access the tumour. Researchers in Dr Oliver Pearce’s lab have found that modifying the tumour’s “sugar-coated” scaffold could help make it easier to treat. #medsky #oncosky 🧪 @qmul.bsky.social

‘Sugar-coated’ tumour matrix may offer way to make triple-negative breast cancer easier to treat

Researchers at Barts Cancer Institute, Queen Mary University of London, have discovered a way in which the environment surrounding triple-negative breast cancer cells helps suppress our immune system,...

bci.qmul.ac.uk

Fantastic experience chairing and organising inaugural London Genome Instability Conference (LOGIC) at @qmbci.bsky.social with @audreylumeau.bsky.social & @mollyguscott.bsky.social , brilliant talks on DNA damage, cancer initiation and genome evolution. Looking forward to doing it again next year!

Excited to share our new paper just out in @cp-cellreports.bsky.social We identified a signalling axis by which monocytes can directly impair NK cell cytotixocity in #metastasis. Led by @ChristosErmogenous and supported by a great team effort @qmbci.bsky.social www.cell.com/cell-reports...

MIF mediates monocyte-dependent inhibition of natural killer cell cytotoxicity in triple-negative breast cancer

Ermogenous et al. show that monocyte-derived MIF suppresses NK cell activation and cytotoxicity through CXCR4, weakening immune control of metastatic seeding in breast cancer. MIF inhibition reverses ...

cell.com

Congratulations to Prof. Louise Jones, who has been elected Fellow of @acmedsci.bsky.social. 👏 Learn more about Prof. Jones' work to understand breast cancer, advance the use of AI in cancer care and realise the potential of personalised medicine ⤵️ @qmul.bsky.social 🧪 #oncosky #medsky

Professor Louise Jones elected Fellow of the Academy of Medical Sciences - Barts Cancer Institute - Queen Mary University of London

Professor Louise Jones at Barts Cancer Institute, Queen Mary University of London, has been elected to the Academy of Medical Sciences. She joins 60 exceptional biomedical and health scientists electe...

bci.qmul.ac.uk

Most of us develop gene mutations linked to blood cancer as we age, but only a small proportion go on to develop the disease. New research from @benjaminwerner.bsky.social and team at BCI explores why, showing how mutated cells compete and evolve over time. 🧪 #medsky #oncosky @qmul.bsky.social

Study offers clues to blood cancer risk, revealing how gene mutations compete over time

Researchers have developed a new way to understand how genetic changes linked to blood cancer evolve in our cells, offering new insight into predicting blood cancer risk.

bci.qmul.ac.uk

Congratulations to Dr @kevinrouault.bsky.social, who has been awarded £1m from @cancerresearchuk.org to launch a clinical trial aiming to improve quality of life for people with myelodysplastic syndromes, a form of blood cancer with limited treatment options. 🧪 #medsky #oncosky @qmul.bsky.social

New £1m clinical trial launches to improve quality of life for people with blood cancer

Researchers have been awarded £1m to launch a new clinical trial for people with myelodysplastic syndromes, a form of blood cancer with limited treatment options.

bci.qmul.ac.uk

🔬 Watch how cancer and immune cells interact in a living system. Scientists at BCI have developed mini lab-grown ovarian tumours that recreate the complex neighbourhood of cells in patients. Published today in @natcomms.nature.com. Read more: bit.ly/4bMCrVg 🧪 #medsky #oncosky @qmul.bsky.social

onlinelibrary.wiley.com/doi/10.1111/... Thrilled to share our work in BJH highlighting the therapeutic potential of targeting the WNT pathway to block the crosstalk among stromal and leukemic ALL cells to prevent chemoresistance. Collab. w/ Bela Wrench @foteinikal.bsky.social @qmbci.bsky.social

Chemotherapy‐driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia

Chemotherapy-induced WNT ligand secretion by bone marrow (BM) stroma drives acute lymphoblastic leukaemia (ALL) chemoresistance. WNT pathway inhibition disrupts this cross-talk and restores therapeut....

onlinelibrary.wiley.com

Congratulations to Professor Michelle Lockley and Dr Oliver Pearce, who have been awarded prestigious @cancerresearchuk.org Programme Foundation Awards, worth nearly £1.5m each. Read more about their work seeking novel cancer therapy targets in our Q&A. 🧪 #medsky #oncosky @qmul.bsky.social

Barts Cancer Institute teams awarded nearly £3m from Cancer Research UK to seek novel cancer therapy targets - Barts Cancer Institute - Queen Mary University of London

Professor Michelle Lockley and Dr Oliver Pearce have both been awarded prestigious Programme Foundation Awards from Cancer Research UK, worth nearly £1.5 million each, to support the work of their res...

bci.qmul.ac.uk

Today, on #WorldCancerDay, we’re taking you behind the scenes at Queen Mary's Barts Cancer Institute and introducing you to the people who are making progress possible. Follow us to stay up to date with new developments. 🧪 #UnitedByUnique #MedSky #OncoSky @qmul.bsky.social @cancerresearchuk.org

Driving discoveries for tomorrow's cancer care at Barts Cancer Institute

YouTube video by BCIQMUL

youtu.be

People with a rare eye cancer (uveal melanoma) that has spread to the liver may survive for longer when doctors take a more active approach to monitoring and treatment, according to results from Professor Hemant Kocher and team. @qmul.bsky.social #medsky #oncosky 🧪

New approach offers hope for people with rare eye cancer - Barts Cancer Institute - Queen Mary University of London

A more active approach to monitoring and treating people with a rare eye cancer (known as uveal melanoma) that has spread to the liver could help some patients to live longer, according to researchers...

bci.qmul.ac.uk

Transgender Awareness Week & we complete our episode with the wonderful Dr Alison Berner⭐️ 🎙️ UCATS & OUTpatients work supporting the transgender community 🎙️Don’t let fear of Saying the wrong thing stop you DOING the right things⭐️ @drallycat.bsky.social @oncodaily.bsky.social @qmbci.bsky.social

📰 15 years of research by Prof. Tatjana Crnogorac-Jurcevic at BCI have led to the launch of Procyon Diagnostics, a new Queen Mary Innovation #spinout company developing a simple test for early #PancreaticCancer detection. @qmul.bsky.social | @qminnovation.bsky.social 🧪 #medsky #oncosky Read more ⤵️

New spinout launches to advance early pancreatic cancer detection

Queen Mary University of London has launched a new company, Procyon Diagnostics, to provide pioneering early cancer detection tests. The company’s first test, PancRISK, offers new hope for detecting p...

bci.qmul.ac.uk

Interested in carrying out research in cancer Radiotherapy and Radiobiology? Applications are open now for our PhD programme for 2026 intake! @kingscollegelondon.bsky.social @qmbci.bsky.social @crick.ac.uk @ucl.ac.uk crukradnet.colcc.ac.uk/phd-students...

PhD Studentships Projects - CRUK RadNet

Applications now open for PhD Studentships for September 2026 The CRUK City of London Radiation Research Centre PhD Programme This is a unique multidisciplinary and collaborative training opportuni...

crukradnet.colcc.ac.uk

The PhD will supervised by both myself and @mirazrahman.bsky.social at @qmbci.bsky.social and @kingscollegelondon.bsky.social, and is an outstanding opportunity to gain expertise in structural biology, medicinal chemistry, and cancer biology, at the cutting edge of translational oncology.

Proud to partner @cancerresearchuk.org and Windsor Fellowship to offer Black Leaders in Cancer #PhD scholarships. Check our projects and apply by Weds 5 Nov: https://www.colcc.ac.uk/black-leaders-phd-programme/ @qmbci.bsky.social @kingslsm.bsky.social @uclmedsci.bsky.social @crick.ac.uk #CRUKFunded

Check out some of the #PhD projects we have on offer, starting Sept 2026. Find out more and apply by noon, Weds 5 Nov: https://www.colcc.ac.uk/phd-studentships/ @qmbci.bsky.social @kingslsm.bsky.social @uclmedsci.bsky.social @crick.ac.uk #CRUKFunded

Our first Centre for Cancer Evolution PI retreat! A wonderful day at Goodenough House discussing science, strategy and forging new collaborations @qmbci.bsky.social

Come and join us at the Barts Cancer Institute @qmbci.bsky.social ! Our medical school, part of Queen Mary University of London @qmulfmd.bsky.social is hiring 10 professors!! www.veredus.co.uk/job/job-747a/. Contact me for a chat if interested.

Professors x 10, Faculty of Medicine & Dentistry | Veredus

QUEEN MARY UNIVERSITY OF LONDON Professors x 10, Faculty of Medicine and Dentistry London Competitive Remuneration Package Queen Mary University of London seeks up to 10 world-leading translational re...

veredus.co.uk

Could imaging, genetic and biomarker tests improve early #ProstateCancer detection? A team led by Prof Prabhakar Rajan @qmbci.bsky.social explore different detection strategies in their latest publication in @bjuijournal.bsky.social. Grab a ☕ and read: doi.org/10.1002/bco2...

📰 A new AI tool could help doctors identify which skin cancers are most likely to spread. We spoke to Professor Alex Wang and Dr Emilia Peleva to find out more about their new study and next steps ⬇ @qmul.bsky.social | @cruk-cityoflondon.bsky.social 🧪 #medsky #oncosky #ArtificialIntelligence

New AI model sheds light on high-risk skin cancer: Q&A with the authors - Barts Cancer Institute - Queen Mary University of London

Researchers at Barts Cancer Institute (BCI), Queen Mary University of London, have developed an artificial intelligence (AI) tool that could help doctors identify which skin cancers are most likely to...

bci.qmul.ac.uk

🎉 Join us in congratulating four BCI researchers who have been promoted! Promoted to Professor: 🔹Professor Angus Cameron 🔹Professor Jun Wang Promoted to Senior Lecturer: 🔹Dr Diu Nguyen Promoted to Reder: 🔹Dr Miguel Ganuza @qmul.bsky.social @qmulfmd.bsky.social @cruk-cityoflondon.bsky.social

📰Rogue DNA rings could provide early clues to brain cancer’s growth, according to new results co-led by Dr @benjaminwerner.bsky.social, as part of international @cancergrand.bsky.social collaboration @qmul.bsky.social | @crick.ac.uk | @stanford.edu | @aacrjournals.bsky.social | #medsky #oncosky 🧪

Rogue’ DNA rings reveal earliest clues to deadly brain cancer’s growth - Barts Cancer Institute - Queen Mary University of London

An international team of scientists has revealed how rogue rings of DNA that float outside of our chromosomes – known as extrachromosomal DNA, or ecDNA – can drive the growth of a large proportion of ...

bci.qmul.ac.uk

📰 NICE has approved a breakthrough life-extending combination treatment for bladder cancer for use in the NHS from today, following trials led by Prof Tom Powles at BCI @qmul.bsky.social. 🧪 #medsky #oncosky #bladdercancer @qmulfmd.bsky.social | @cruk-cityoflondon.bsky.social

Breakthrough life-extending treatment for advanced bladder cancer available on NHS - Barts Cancer Institute - Queen Mary University of London

The new combination treatment offers hope to thousands of people living with advanced urothelial cancer. The clinical trials, led by Professor Tom Powles at Barts Cancer Institute, Queen Mary University of London, showed that overall survival rates were almost twice as long with this new treatment compared to the current standard treatment.

bci.qmul.ac.uk

Proud to be named as a finalist in the University of the Year category in the 2025 UK Social Mobility Awards, which recognise organisations taking action to level the playing field for people from less-advantaged socio-economic backgrounds. Roll on October 2nd when the winners will be announced!